<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080921</url>
  </required_header>
  <id_info>
    <org_study_id>CS. ƒêT.19H2</org_study_id>
    <nct_id>NCT04080921</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis</brief_title>
  <official_title>The Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis at Vinmec International Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Research Institute of Stem Cell and Gene Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Research Institute of Stem Cell and Gene Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of autologous bone marrow-derived mononuclear cell
      transplantation in-patient with neurological sequelae due to encephalitis or meningitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of autologous bone
      marrow-derived mononuclear cell in 22 patients with neurological sequelae due to encephalitis
      or meningitis at Vinmec International Hospital, Hanoi, Vietnam
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2014</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMFM-88</measure>
    <time_frame>Baseline, 6 months, and 12 months after transplantation</time_frame>
    <description>Change in Total Score of Gross Motor Function Measure GMFM-88</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle tone</measure>
    <time_frame>Baseline, 6 months, and 12 months after transplantation</time_frame>
    <description>Muscle tone are assessed by Modified Ashworth Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Through study completion, an average of 12 months</time_frame>
    <description>Examples of adverse events to look for: fever, infections, vomit, epilepsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Encephalitis</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>Stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Stem cell transplantation</intervention_name>
    <description>Transplantation of Autologous Bone Marrow Mononuclear Cells</description>
    <arm_group_label>Stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neurological sequelae due to encephalitis or meningitis

        Exclusion Criteria:

          -  Coagulation disorders

          -  Allergy to anesthetic agents

          -  Severe health conditions such as cancer, failure of heart, lung, liver or kidney

          -  Active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liem T Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinmec Research Institute of Stem Cell and Gene Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vinmec Research Institute of Stem Cell and Gene Technology</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Bansal H, Singh L, Verma P, Agrawal A, Leon J, Sundell IB, Koka PS. Administration of Autologous Bone Marrow-Derived Stem Cells for Treatment of Cerebral Palsy Patients: A Proof of Concept. J Stem Cells. 2016;11(1):37-49.</citation>
    <PMID>28296863</PMID>
  </results_reference>
  <results_reference>
    <citation>Nguyen LT, Nguyen AT, Vu CD, Ngo DV, Bui AV. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC Pediatr. 2017 Apr 12;17(1):104. doi: 10.1186/s12887-017-0859-z.</citation>
    <PMID>28403842</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>encephalitis</keyword>
  <keyword>meningitis</keyword>
  <keyword>neurological sequelae due</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

